CRISPR Therapeutics could start reporting product revenue soon.Vertex Pharmaceuticals (VRTX 0.43%) has made it to the major leagues in the world of biotech. The company is the leading maker of cystic fibrosis (CF) treatments, with its products generating more than $9.8 billion in revenue last year. Vertex also recently submitted its latest CF candidate to regulators for consideration -- and an approval could truly cement its long-term dominance.On top of this, late last year Vertex won approval -- along wit ...